Kátia M Lima, Juliana P Vago, Thaís R Caux, Graziele Letícia Negreiros-Lima, Michelle A Sugimoto, Luciana P Tavares, Raquel G Arribada, Aline Alves F Carmo, Izabela Galvão, Bruno Rocha C Costa, Frederico M Soriani, Vanessa Pinho, Egle Solito, Mauro Perretti, Mauro M Teixeira, Lirlândia P Sousa
Annexin A1 (AnxA1) is a glucocorticoid-regulated protein known for its anti-inflammatory and pro-resolving effects. We have shown previously that the cAMP-enhancing compounds rolipram (ROL; a PDE4 inhibitor) and Bt2 cAMP (a cAMP mimetic) drive caspase-dependent resolution of neutrophilic inflammation. In this follow-up study, we investigated whether AnxA1 could be involved in the pro-resolving properties of these compounds using a model of LPS-induced inflammation in BALB/c mice. The treatment with ROL or Bt2 cAMP at the peak of inflammation shortened resolution intervals, improved resolution indices, and increased AnxA1 expression...
August 18, 2017: Journal of Biological Chemistry